Clinical Trial Update: Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial updating safety and bioactivity of ipilimumab plus nivolumab before liver resection in hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Imperial College London | Conditions: Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: UNKNOWN